Want to see STRO full AI Analyst Report?
Top Page
Sutro Biopharma
(NASDAQ:STRO)
Select Model
Select Model
Rating:42Neutral
Price Target:
$18.50
▼(-13.67% Downside)
Action:Reiterated
Date:08/17/26
The score is weighed down primarily by weak financial performance (large operating losses, sharp revenue decline, heavy ongoing cash burn, and negative equity). Technical indicators also point to a sustained downtrend (price below key moving averages and negative MACD), with only a modest offset from near-oversold readings. Valuation offers limited support because the negative P/E reflects continued losses and dividend yield data is not available.
Positive Factors
STRO-004 Clinical Differentiation
Early partial responses, favorable tolerability, predictable pharmacokinetics, and only 6% adverse-event discontinuation support STRO-004’s potential differentiation. If sustained, this profile could broaden dosing and combination opportunities while validating Sutro’s ADC platform.
Negative Factors
Sharp Revenue Contraction
TTM revenue fell 54.1%, reversing prior modest growth and highlighting volatility in Sutro’s collaboration-driven top line. Uneven partner activity and milestone timing can make funding visibility less predictable while internal and partnered programs remain in development.
Read all positive and negative factors
Positive Factors
Negative Factors
STRO-004 Clinical Differentiation
Early partial responses, favorable tolerability, predictable pharmacokinetics, and only 6% adverse-event discontinuation support STRO-004’s potential differentiation. If sustained, this profile could broaden dosing and combination opportunities while validating Sutro’s ADC platform.
Read all positive factors
Sutro Biopharma (STRO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$332.78M
Dividend YieldN/A
Average Volume (3M)245.18K
Price to Earnings (P/E)―
Beta (1Y)3.27
Revenue Growth-56.25%
EPS Growth30.97%
CountryUS
Employees128
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-17.42
Shares Outstanding16,581,171
10 Day Avg. Volume155,126
30 Day Avg. Volume245,183
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.74
Price to Sales (P/S)0.96
P/FCF Ratio-0.55
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$51.17Price Target Upside138.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-8.21
Revenue Forecast (FY)$49.57M
Sutro Biopharma Business Overview & Revenue Model
Company Description
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions lik...
How the Company Makes Money
Sutro Biopharma primarily generates revenue through (1) collaboration and license agreements and (2) other related research and development services performed for partners; it does not rely on recurring product sales in the way a commercial-stage ...
Sutro Biopharma Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
18
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.70M | 102.48M | 62.04M | 153.73M | 67.77M | 61.88M |
| Gross Profit | 44.42M | 95.16M | 54.83M | 146.91M | 59.48M | 52.11M |
| EBITDA | -134.60M | -145.65M | -180.45M | -67.92M | -105.07M | -97.56M |
| Net Income | -180.64M | -191.09M | -227.46M | -106.79M | -119.20M | -105.54M |
Balance Sheet | ||||||
| Total Assets | 194.46M | 173.83M | 387.21M | 470.74M | 406.94M | 341.41M |
| Cash, Cash Equivalents and Short-Term Investments | 164.35M | 141.43M | 316.89M | 375.62M | 334.36M | 197.94M |
| Total Debt | 10.78M | 15.67M | 23.15M | 33.63M | 55.02M | 57.37M |
| Total Liabilities | 297.78M | 306.28M | 342.61M | 321.09M | 189.90M | 88.84M |
| Stockholders Equity | -103.32M | -132.45M | 44.60M | 149.65M | 217.05M | 252.56M |
Cash Flow | ||||||
| Free Cash Flow | -145.62M | -178.93M | -194.64M | -115.93M | -4.31M | -97.00M |
| Operating Cash Flow | -145.17M | -177.23M | -191.54M | -111.62M | 3.55M | -81.68M |
| Investing Cash Flow | 32.79M | 45.01M | 218.51M | -3.92M | -35.02M | -97.31M |
| Financing Cash Flow | 102.69M | 44.00K | 94.05M | 137.55M | 48.31M | 3.26M |
Sutro Biopharma Technical Analysis
Negative
21.43
Price Trends
24.59
Negative
28.33
Negative
22.26
Negative
Market Momentum
-1.16
Negative
36.81
Neutral
37.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STRO, the sentiment is Negative. The current price of 21.43 is below the 20-day moving average (MA) of 21.47, below the 50-day MA of 24.59, and below the 200-day MA of 22.26, indicating a bearish trend. The MACD of -1.16 indicates Negative momentum. The RSI at 36.81 is Neutral, neither overbought nor oversold. The STOCH value of 37.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STRO.
Sutro Biopharma Risk Analysis
Sutro Biopharma disclosed 78 risk factors in its most recent earnings report. Sutro Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sutro Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $613.98M | 49.42 | 1.91% | ― | -15.05% | ― | |
56 Neutral | $629.54M | -12.03 | -16.59% | ― | 67.01% | 40.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $462.57M | -3.76 | -45.45% | ― | 2.33% | 36.86% | |
46 Neutral | $300.20M | -1.58 | -33.22% | ― | 215.59% | 22.48% | |
43 Neutral | $173.63M | -2.05 | 44.63% | ― | 3.03% | 57.71% | |
42 Neutral | $332.78M | -1.15 | 185.30% | ― | -56.25% | 30.97% |
* Healthcare Sector Average
STRO
Sutro Biopharma
19.10
9.39
96.77%
ARVN
Arvinas Holding Company
9.08
1.08
13.50%
BCYC
Bicycle Therapeutics
4.18
-2.94
-41.29%
ADCT
ADC Therapeutics
1.30
-2.02
-60.84%
CCCC
C4 Therapeutics
3.55
0.87
32.46%
OABI
OmniAb
4.24
2.67
170.06%
Sutro Biopharma Corporate Events
Business Operations and StrategyFinancial Disclosures
Sutro Biopharma Q2 Results Highlight Advancing ADC Pipeline
Positive
Aug 12, 2026
On August 12, 2026, Sutro Biopharma reported second quarter 2026 financial results and released new clinical data from its Phase 1 STRIVE-01 study of STRO-004, a Tissue Factor-targeting DAR8 exatecan ADC in heavily pretreated patients with advance...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.